Austin, Texas, United StatesFounded 200764+ employeesSVRA
$746.8M raisedIPO· last: post ipo debt (Jan 2026)· 18 rounds
Backed by(22 investors)
Hercules Capital · LeadRTW Investments · LeadBain Capital Life Sciences · LeadCystic Fibrosis Foundation · LeadHaas Portman · LeadKeiretsu Forum Mid Atlantic · LeadSilicon Valley Bank · Lead+7 more
1 layoff event · Last: Dec 2020
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. More information on the Phase 3 IMPALA-2 clinical trial in aPAP can be found at www.impala2.com
